AXGT:NSD-Sio Gene Therapies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.56

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

1.54M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

Sio Gene Therapies, Inc (AXGT) Stock Analysis:
Based on the Sio Gene Therapies, Inc stock forecasts from 0 analysts, the average analyst target price for Sio Gene Therapies, Inc is not available over the next 12 months. Sio Gene Therapies, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sio Gene Therapies, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Sio Gene Therapies, Inc’s stock price was USD 2.56. Sio Gene Therapies, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Sio Gene Therapies, Inc
No recent average analyst rating found for Sio Gene Therapies, Inc

About

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-G ...Read More

Company Website : http://www.axovant.com

Address : 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB

Employees : 38

Fiscal Year End : March

Currency: USD

Country : USA

Technical Indicators

Beta : 1.58

Short Ratio : 0.65

Shorted Shares : 1,440,108

200 Day Moving Average : 3.10

Shorted Shares Previous Month : 526,502

50 Day Moving Average : 2.84

Shares Held By Insiders : 39.57%

Short Percentage : 6.72%

Shares Held by Institutions : 24.27%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

 USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

 USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

 USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

 USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

N/A

 USD19.45B 58.02 5.06
ARGX argenx SE

N/A

 USD17.61B N/A N/A

ETFs Containing AXGT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -98.59% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.59% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.21% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.21% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.28% N/A N/A N/A N/A
Risk Adjusted Return -96.21% N/A N/A N/A N/A
Market Capitalization 0.10B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.73 N/A N/A N/A N/A
Price / Cash Flow Ratio -1.47 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -78.49% N/A N/A N/A N/A
Return on Assets -37.29% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.65 N/A N/A N/A N/A
Short Percent 6.72% N/A N/A N/A N/A
Beta 1.58 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.